Abstract
Spinal Muscular Atrophy (SMA) is a progressive neurodegenerative disorder characterised by the loss of upper and/or lower motor neurons. SMA is the leading genetic cause of infant mortality with an incidence of 1 in 6000 live births and a carrier frequency of about 1 in 50. Different types of disease (from SMAI to SMAV) have been described based on clinical severity and age of onset. The SMA-determining gene, Survival of Motor Neurons (SMN), is part of a 500 kb-inverted duplication on chromosome 5q13. Within the duplicated genes SMN1 and SMN2 can be found. Most (95%) SMA patients have deletions or conversion events of SMN1. The SMN2 gene primarily produces a transcript which lacks exon 7 and of which only 10-20% of its protein is functional. Although a variety of therapeutic trials are ongoing, only life-prolonging treatments are being developed. The knowledge gained regarding the pathogenesis of SMA remains limited, because the precise function of SMN is not yet known. Furthermore, it is not quite clear why motor neurons of the patients are the only cell type for which SMN expression level are unadequate for their normal activity, even if the affected genes have “housekeeping” functions. Both pharmacological or genetic approaches have been conducted for the therapy of SMA. Moreover, stem cells provide a further aspect to be analysed. In fact, the genetic modification of a small number of stem cells could give rise to a dividing population of therapeutic cells. These innovative approaches when united could be usefully adopted to replace lost cells and at the same time protect surviving motor neurons in SMA patients.
Keywords: Spinal Muscular Atrophy, gene therapy, gene targeting, pharmacological treatment, survival motor neuron gene
Current Genomics
Title: Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy (SMA) Disease
Volume: 7 Issue: 6
Author(s): Federica Sangiuolo, Annalisa Botta, Antonio Filareto, Paola Spitalieri and Giuseppe Novelli
Affiliation:
Keywords: Spinal Muscular Atrophy, gene therapy, gene targeting, pharmacological treatment, survival motor neuron gene
Abstract: Spinal Muscular Atrophy (SMA) is a progressive neurodegenerative disorder characterised by the loss of upper and/or lower motor neurons. SMA is the leading genetic cause of infant mortality with an incidence of 1 in 6000 live births and a carrier frequency of about 1 in 50. Different types of disease (from SMAI to SMAV) have been described based on clinical severity and age of onset. The SMA-determining gene, Survival of Motor Neurons (SMN), is part of a 500 kb-inverted duplication on chromosome 5q13. Within the duplicated genes SMN1 and SMN2 can be found. Most (95%) SMA patients have deletions or conversion events of SMN1. The SMN2 gene primarily produces a transcript which lacks exon 7 and of which only 10-20% of its protein is functional. Although a variety of therapeutic trials are ongoing, only life-prolonging treatments are being developed. The knowledge gained regarding the pathogenesis of SMA remains limited, because the precise function of SMN is not yet known. Furthermore, it is not quite clear why motor neurons of the patients are the only cell type for which SMN expression level are unadequate for their normal activity, even if the affected genes have “housekeeping” functions. Both pharmacological or genetic approaches have been conducted for the therapy of SMA. Moreover, stem cells provide a further aspect to be analysed. In fact, the genetic modification of a small number of stem cells could give rise to a dividing population of therapeutic cells. These innovative approaches when united could be usefully adopted to replace lost cells and at the same time protect surviving motor neurons in SMA patients.
Export Options
About this article
Cite this article as:
Sangiuolo Federica, Botta Annalisa, Filareto Antonio, Spitalieri Paola and Novelli Giuseppe, Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy (SMA) Disease, Current Genomics 2006; 7 (6) . https://dx.doi.org/10.2174/138920206778948691
DOI https://dx.doi.org/10.2174/138920206778948691 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Autophagy in the Pathogenesis of Ischemic Stroke
Current Neuropharmacology The Current View on the Helicase Activity of RNA Helicase A and Its Role in Gene Expression
Current Protein & Peptide Science Hybrid Molecules Incorporating Natural Products: Applications in Cancer Therapy, Neurodegenerative Disorders and Beyond
Current Medicinal Chemistry DNA Repair in Premature Aging Disorders and Neurodegeneration
Current Aging Science Functional Neuroproteomics: An Imperative Approach for Unravelling Protein Implicated Complexities of Brain
CNS & Neurological Disorders - Drug Targets HPTLC Analysis with the Effect of <i>Bacopa monnieri, Evolvulus alsinoides</i> and <i>Tinospora cordifolia</i> against Scopolamine-Induced Amnesic Rats
Drug Delivery Letters Editorial [Hot topic: Prion Diseases: Targets and Treatments of Symptoms and Disease Progression (Guest Editor: Brian Appleby)]
CNS & Neurological Disorders - Drug Targets The Protective Effects of Natural Products on Blood-Brain Barrier Breakdown
Current Medicinal Chemistry Studying the Effects of Classic Hallucinogens in the Treatment of Alcoholism: Rationale, Methodology, and Current Research with Psilocybin
Current Drug Abuse Reviews Role of microRNAs on Blood Brain Barrier Dysfunction in Vascular Cognitive Impairment
Current Drug Delivery Inflammatory Cyclooxygenase Activity and PGE<sub>2</sub> Signaling in Models of Alzheimer’s Disease
Current Immunology Reviews (Discontinued) Treating Asthma as a Neuroelectrical Disorder
Inflammation & Allergy - Drug Targets (Discontinued) Commentary-1 Research Highlights (Never Underestimate the Power of Adenosine in Multiple Sclerosis)
CNS & Neurological Disorders - Drug Targets Skeletal Muscle in Motor Neuron Diseases: Therapeutic Target and Delivery Route for Potential Treatments
Current Drug Targets VIP-induced Neuroprotection of the Developing Brain
Current Pharmaceutical Design Neurological Aspects of Medical Use of Cannabidiol
CNS & Neurological Disorders - Drug Targets β-amyloid and Oxidative Stress: Perspectives in Drug Development
Current Pharmaceutical Design Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Current Pharmaceutical Design The Role of Inflammation in Epilepsy
Current Pediatric Reviews